|Chemical and physical data|
|Molar mass||409.501 g/mol g·mol−1|
|3D model (JSmol)|
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.
- Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi:10.1016/j.coph.2011.01.004. hdl:10171/18451. PMID 21330210.
- Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN 978-0-12-385902-0. Retrieved 25 October 2011.
- Drug Profile: Cerlapirdine
|AChE inhibitor medications|
|Experimental BACE inhibitors|